BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22379747)

  • 1. Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients.
    Sornmayura P; Rerkamnuaychoke B; Jinawath A; Euanorasetr C
    J Med Assoc Thai; 2012 Jan; 95(1):88-95. PubMed ID: 22379747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
    Hofmann M; Stoss O; Shi D; Büttner R; van de Vijver M; Kim W; Ochiai A; Rüschoff J; Henkel T
    Histopathology; 2008 Jun; 52(7):797-805. PubMed ID: 18422971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
    Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
    Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
    López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
    Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
    Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
    Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
    Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
    Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization.
    Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
    Cancer; 2012 Feb; 118(4):914-23. PubMed ID: 21800290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
    Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
    Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases.
    Staněk L; Rozkoš T; Laco J; Ryška A; Petruželka L; Důra M; Dundr P
    Mol Med Rep; 2014 Nov; 10(5):2669-74. PubMed ID: 25189406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
    Park IH; Kwon Y; Ro JY; Lee KS; Ro J
    Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.